Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...
It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.
Analyst Brian Cheng of J.P. Morgan maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $46.00.Invest with ...
KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, ...
Denver Location Boasts Private Infusion Suites for Addressing Patients’ Specialty Therapy Needs Soleo Health, an innovative ...
SG Americas Securities LLC increased its position in argenx SE (NASDAQ:ARGX – Free Report) by 6.2% in the 4th quarter, ...
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Myasthenia gravis is a serious, rare, and chronic neuromuscular autoimmune disease that can cause debilitating and potentially life-threatening muscle weakness. There are around 60,000 to 120,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback